Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting
April 05 2021 - 7:30AM
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company
dedicated to the development of innovative therapeutics for
neurotology, today announced the presentation of previously
disclosed clinical results from the successful OTO-313 Phase 1/2
trial at the upcoming American Neurotology Society’s 56th Annual
Spring Meeting, which is part of the Combined Otolaryngology Spring
Meeting (COSM), to be held virtually April 7-11, 2021. The oral
presentation will be delivered on April 10, 2021 at 5:07 p.m. EDT
by Kenneth Maxwell, M.D., a Neurotologist at Piedmont Ear Nose
& Throat Associates in Winston-Salem, North Carolina. Dr.
Maxwell was an investigator in the trial.
“We are pleased to have the opportunity to present clinical
results from the OTO-313 Phase 1/2 trial to the neurotology
community during the COSM conference,” said David A. Weber, Ph.D.,
president and CEO of Otonomy. “Tinnitus is a common condition seen
by neurotologists who unfortunately have no approved drug
treatments to offer patients. The Phase 2 trial we recently
initiated builds on the encouraging Phase 1/2 results and is a
significant step forward for this important program.”
About OtonomyOtonomy is a biopharmaceutical
company dedicated to the development of innovative therapeutics for
neurotology. The company pioneered the application of drug delivery
technology to the ear in order to develop products that achieve
sustained drug exposure from a single local administration. This
approach is covered by a broad patent estate and is being utilized
to develop a pipeline of products addressing important unmet
medical needs with a focus on hearing loss and tinnitus. For
additional information please visit www.otonomy.com.
Contacts:
Media Inquiries:Spectrum ScienceChloé-Anne RamseyVice
President404.865.3601cramsey@spectrumscience.com
Investor Inquiries:Westwicke ICRRobert H. UhlManaging
Director858.356.5932robert.uhl@westwicke.com
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Aug 2023 to Aug 2024